Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 02, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Date: November 02, 2006.
- Price per Share: 1,410.16 pence.
- Total Treasury Shares Held: 212,769,678 shares following the transaction.
- Shares in Issue: 5,775,415,132 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 1,000,000 shares to be held in Treasury. Consequently, the total number of shares held in Treasury increased to 212,769,678, while the number of shares in issue stands at 5,775,415,132.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 1,000,000 share repurchase (1,000,000 shares x 1,410.16 pence).
- Confirm the updated share capital structure: 5,775,415,132 shares in issue versus 212,769,678 in Treasury.
- Review the original shareholder resolution from the May 17, 2006 Annual General Meeting to understand the full scope of the authorized buyback program.
- Note that this filing does not contain operational or financial performance data for the period.